{"doi":"10.1002/ajh.25445","title":"Toxicities of CD19 CAR‐T cell immunotherapy","abstract":"<jats:title>Abstract</jats:title><jats:p>CD19‐targeted chimeric antigen receptor (CAR)‐modified T (CAR‐T) cell immunotherapy has demonstrated impressive results in B‐cell malignancies, and CAR‐T cell therapies targeting other antigens are in development for other cancers. Cytokine release syndrome (CRS) and neurotoxicity can be life‐threatening in a subset of patients. The severity of CRS and neurotoxicity can be impacted by the disease burden, lymphodepletion regimen, and CAR‐T cell dose. Tocilizumab and corticosteroids have been used to manage these toxicities, enabling CD19 CAR‐T cells to be administered without obvious compromise in efficacy. Consensus criteria for grading and managing toxicities will facilitate the widespread application of this treatment modality.</jats:p>","journal":"American Journal of Hematology","year":2019,"id":588834,"datarank":6.336013898627228,"base_score":4.941642422609304,"endowment":4.941642422609304,"self_citation_contribution":0.7412463633913957,"citation_network_contribution":5.594767535235833,"self_endowment_contribution":0.7412463633913957,"citer_contribution":5.594767535235833,"corpus_percentile":null,"corpus_rank":null,"citation_count":139,"citer_count":135,"citers_with_citation_signal":115,"citers_with_endowment":115,"datacite_reuse_total":6,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":3668,"name":"Cameron J. Turtle","orcid":"0000-0002-4722-4461","position":1,"is_corresponding":false},{"id":233384,"name":"Alexandre V. Hirayama","orcid":"0000-0001-7980-3882","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Toxicities of CD19 CAR‐T cell immunotherapy","abstract":"<jats:title>Abstract</jats:title><jats:p>CD19‐targeted chimeric antigen receptor (CAR)‐modified T (CAR‐T) cell immunotherapy has demonstrated impressive results in B‐cell malignancies, and CAR‐T cell therapies targeting other antigens are in development for other cancers. Cytokine release syndrome (CRS) and neurotoxicity can be life‐threatening in a subset of patients. The severity of CRS and neurotoxicity can be impacted by the disease burden, lymphodepletion regimen, and CAR‐T cell dose. Tocilizumab and corticosteroids have been used to manage these toxicities, enabling CD19 CAR‐T cells to be administered without obvious compromise in efficacy. Consensus criteria for grading and managing toxicities will facilitate the widespread application of this treatment modality.</jats:p>","is_dataset_classified":null,"base_score":4.941642422609304,"endowment":4.941642422609304,"datacite_reuse_total":6,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"30784102","pmcid":null,"openalex_id":"https://openalex.org/W2916176185","authors":[],"funders":[{"funder_name":"Nektar Therapeutics","grant_id":"","title":null},{"funder_name":"Juno Therapeutics","grant_id":"","title":null},{"funder_name":"Juno Therapeutics","grant_id":"","title":null},{"funder_name":"Nektar Therapeutics","grant_id":"","title":null}],"total_grants":4,"fwci":8.3957,"citation_percentile":0.98373811,"influential_citations":3,"citation_trend":[{"year":2019,"count":5},{"year":2020,"count":29},{"year":2021,"count":25},{"year":2022,"count":31},{"year":2023,"count":21},{"year":2024,"count":18},{"year":2025,"count":6},{"year":2026,"count":4}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25445","host_type":"BRONZE"},{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fajh.25445","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25445","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ajh.25445","host_type":"publisher"},{"url":"https://doi.org/10.1002/ajh.25445","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/30784102","host_type":"repository"}],"fields_of_study":["CAR-T cell therapy research","Medicine","Antigens, CD19","Cytokine Release Syndrome","Humans","Immunotherapy, Adoptive","Neurotoxicity Syndromes","Receptors, Antigen, T-Cell"],"mesh_terms":["Cytokine Release Syndrome","Humans","Receptors, Antigen, T-Cell","Immunotherapy, Adoptive","Antigens, CD19","Neurotoxicity Syndromes"],"keywords":["Immunotherapy","Medicine","CD19","Internal medicine","Cancer research","Immunology","Antigen","Cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.14121801.v1","title":"Additional file 1 of Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.14121801","title":"Additional file 1 of Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.21099094.v1","title":"Additional file 1 of Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.21099094","title":"Additional file 1 of Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.21099097","title":"Additional file 2 of Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.21099097.v1","title":"Additional file 2 of Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk","publisher":"figshare","resource_type":"Dataset"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-22T22:34:33.751218Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}